Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 100%Moderate 0 · 0%High 0 · 0%

Alemtuzumab 24 mg vs interferon beta‐1a

Sustained disease progression‐free survival · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…

Alemtuzumab 24 mg may leads to lower sustained disease progression‐free survival compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Alemtuzumab for multiple sclerosis 2023 · Cochrane Headline outcomes only
HR 0.33 [0.16, 0.69]
1 study · 221 participants
Low

Alemtuzumab 12 mg vs interferon beta‐1a

Sustained disease progression‐free survival · adults with relapsing–remitting multiple sclerosis

Alemtuzumab 12 mg may leads to lower sustained disease progression‐free survival compared with interferon beta‐1a (low certainty).

1 finding from 1 review

Alemtuzumab for multiple sclerosis 2023 · Cochrane Headline outcomes only
HR 0.25 [0.11, 0.56]
1 study · 223 participants
Low